TBPH Theravance Biopharma, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Theravance Biopharma, Inc. (TBPH) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 23, 2026, a 10-Q quarterly report filed on November 12, 2025, an 8-K current report filed on March 30, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Theravance Biopharma, Inc. (TBPH) (SEC CIK 1583107), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Item 2.02 reference indicates earnings or financial results disclosed via Exhibit 99.1
- • No specific financial figures or period details provided in the text itself
Item 2.05: Costs Associated with Exit or Disposal Activities
- • Workforce cut ~50%, cost base reduced ~60% (~$70M in annual savings)
- • One-time cash severance costs estimated $5M–$7M over next two quarters
Item 2.02: Results of Operations and Financial Condition
- • YUPELRI sales growth and royalty payments cited as key forward-looking focus areas for the company
- • Ampreloxetine program and R&D function being wound down; G&A also significantly reduced — signals major cost restructuring underway
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Theravance Biopharma, Inc. (TBPH) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 30, 2026 | — | — | — |
10-K | Mar 23, 2026 | Dec 31, 2025 | — | |
8-K | Mar 19, 2026 | — | Analysis | — |
8-K | Mar 3, 2026 | — | Analysis | — |
8-K | Jan 12, 2026 | — | — | |
8-K | Dec 8, 2025 | — | — | |
10-Q | Nov 12, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 13, 2025 | Jun 30, 2025 | — | |
10-Q | May 12, 2025 | Mar 31, 2025 | — | |
10-K | Mar 7, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 14, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | May 15, 2024 | Mar 31, 2024 | — | |
10-K | Mar 1, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 9, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 9, 2023 | Jun 30, 2023 | — | |
10-Q | May 10, 2023 | Mar 31, 2023 | — | |
10-K | Mar 1, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 9, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 8, 2022 | Jun 30, 2022 | — | |
10-Q | May 6, 2022 | Mar 31, 2022 | — | |
10-K | Feb 28, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 8, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 5, 2021 | Jun 30, 2021 | — | |
10-Q | May 6, 2021 | Mar 31, 2021 | — |
Frequently Asked Questions
What are the latest TBPH SEC filings in 2026?
Theravance Biopharma, Inc. (TBPH) has filed a 10-K annual report on March 23, 2026, a 10-Q quarterly report on November 12, 2025, an 8-K current report on March 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did TBPH file its most recent 10-K annual report?
Theravance Biopharma, Inc. (TBPH) filed its most recent 10-K annual report on March 23, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view TBPH 10-Q quarterly reports?
Theravance Biopharma, Inc. (TBPH)'s most recent 10-Q quarterly report was filed on November 12, 2025. SignalX displays every TBPH 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has TBPH filed recently?
Theravance Biopharma, Inc. (TBPH)'s most recent 8-K was filed on March 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find TBPH insider trading activity (Form 4)?
SignalX aggregates every TBPH Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does TBPH file with the SEC?
Theravance Biopharma, Inc. (TBPH) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new TBPH filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Theravance Biopharma, Inc. (TBPH).
What is TBPH's SEC CIK number?
Theravance Biopharma, Inc. (TBPH)'s SEC CIK (Central Index Key) number is 1583107. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1583107 to look up all TBPH filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find TBPH return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Theravance Biopharma, Inc. (TBPH) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Theravance Biopharma, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 49+ filings.